» » Efalizumab and Psoriasis (Pocket Pharma)
eBook Efalizumab and Psoriasis (Pocket Pharma) download
Medical Books
Author: Alan Menter
ISBN: 1858738237
Subcategory: Medicine
Pages 56 pages
Publisher Science Press (March 1, 2004)
Language English
Category: Medical Books
Rating: 4.7
Votes: 126
ePUB size: 1266 kb
FB2 size: 1335 kb
DJVU size: 1144 kb
Other formats: azw lrf docx lit

eBook Efalizumab and Psoriasis (Pocket Pharma) download

by Alan Menter


Safety and adverse events In: Pocket Pharma: Efalizumab and Psoriasis. Because T-cell interactions are involved in the pathophysiology of psoriasis, therapy with a T-cell modulator may have beneficial effects on psoriasis severity and health-related quality of life (HRQL).

Safety and adverse events In: Pocket Pharma: Efalizumab and Psoriasis. Psoriasis causes as much disability as other major medical diseases. To assess the efficacy and safety of efalizumab, a T-cell modulator, in patients with plaque psoriasis.

Efalizumab-treated subjects exhibited significantly greater mean . Cather JC, Cather JC, Menter A. Modulating T cell responses for the treatment of psoriasis: a focus on efalizumab.

Cather JC, Cather JC, Menter A.

Efalizumab is a humanised monoclonal antibody targeting the CD11a subunit of lymphocyte function-associated antigen-1, specifically developed for psoriasis

Efalizumab is a humanised monoclonal antibody targeting the CD11a subunit of lymphocyte function-associated antigen-1, specifically developed for psoriasis. Indicated for patients with moderate-to-severe plaque psoriasis, efalizumab is FDA-approved in the US for patients aged or 18, as well as being approved in several other European countries. Clinical studies have proven the efficacy of efalizumab for a majority of patients, improving quality of life with continuous maintenance therapy by means of weekly subcutaneous self-injections.

It allows safe and effective long-term control of psoriasis. Therefore, evidence-based treatment guidelines recommend its use in moderate to severe plaque-type psoriasis. Efalizumab in the treatment of psoriasis. oceedings{abIT, title {Efalizumab in the treatment of psoriasis}, author {W Boehncke}, booktitle {Biologics : targets & therapy}, year {2007} }. W Boehncke. Published in Biologics : targets & therapy 2007.

As implied by the suffix -mab, it is a recombinant humanized monoclonal antibody administered once weekly by subcutaneous injection.

Psoriasis is a chronic condition with serious quality-of-life ramifications. Psoriasis is a chronic condition with serious quality-of-life ramifications. Dermatologists seek alternative treatments of patients with plaque psoriasis that provide both efficacy and safety while minimizing exposure to high-potency steroids that can have adverse effects following long-term use.

Cather JC, Menter A (2005) Efalizumab: continuous therapy for chronic psoriasis. Expert Opin Biol Ther 5: 393–gle Scholar.

J Am Acad Dermatol 2005; 52: 425-33. Menter A, Gordon KB, Carey W et al. Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis. Arch Dermatol 2005; 141: 31-8.

Efalizumab; Nail; Palmoplantar; Psoriasis; Scalp Re-use of this article is permitted in accordance with the Terms and Conditions set out at interscience. Psoriasis occurs in approximately 1 3% of the population in Europe and the USA 2 2 Takahashi et al. many topical treatments or phototherapy because of the impermeability of the nail plate and the protective effects of hair on the scalp.